Updated efficacy, safety, & PD-L1 status of patients with HR+, HER2- metastatic breast cancer administered abemaciclib plus pembrolizumab.
Sara M. Tolaney(Harvard University), Hope S. Rugo(City of Hope), Luca Gianni(Fondazione Michelangelo), Maura N. Dickler(Memorial Sloan Kettering Cancer Center), Yi Lu(Shandong Provincial Hospital), Peter Kabos(University of Colorado Anschutz Medical Campus), Suzanne R.L. Young(Eli Lilly (United States)), Valerie M. Jansen(New York Oncology Hematology)
Cited by 40
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k